Michael Chorny

Summary

Affiliation: The Children's Hospital of Philadelphia
Country: USA

Publications

  1. ncbi Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles
    Michael Chorny
    Department of Pediatrics, The Children s Hospital of Philadelphia, Abramson Research Bldg, Ste 702, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Control Release 146:144-51. 2010
  2. ncbi Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharm Res 29:1232-41. 2012
  3. ncbi Magnetic nanoparticles for targeted vascular delivery
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA
    IUBMB Life 63:613-20. 2011
  4. ncbi Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    J Biomed Mater Res A 78:276-82. 2006
  5. ncbi A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles
    Einat Cohen-Sela
    Department of Pharmaceutics, Faculty of Medicine, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Control Release 133:90-5. 2009
  6. ncbi Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells
    Michael Chorny
    The Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Mol Pharm 6:1380-7. 2009
  7. ncbi High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents
    Boris Polyak
    Department of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Proc Natl Acad Sci U S A 105:698-703. 2008
  8. ncbi Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity
    Einat Cohen-Sela
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P O Box 12065, Jerusalem 91120, Israel
    J Pharm Sci 98:1452-62. 2009
  9. ncbi Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Methodist Debakey Cardiovasc J 8:23-7. 2012
  10. ncbi Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:8346-51. 2010

Collaborators

Detail Information

Publications18

  1. ncbi Endothelial delivery of antioxidant enzymes loaded into non-polymeric magnetic nanoparticles
    Michael Chorny
    Department of Pediatrics, The Children s Hospital of Philadelphia, Abramson Research Bldg, Ste 702, 3615 Civic Center Blvd, Philadelphia, PA 19104, USA
    J Control Release 146:144-51. 2010
    ..This protective effect of magnetically targeted MNP impregnated with antioxidant enzymes can be highly relevant for the treatment of cardiovascular disease and should be further investigated in animal models...
  2. ncbi Formulation and in vitro characterization of composite biodegradable magnetic nanoparticles for magnetically guided cell delivery
    Michael Chorny
    Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharm Res 29:1232-41. 2012
    ..This study focused on select variables controlling the uptake and cell compatibility of biodegradable polymer-based MNP in cultured endothelial cells...
  3. ncbi Magnetic nanoparticles for targeted vascular delivery
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA
    IUBMB Life 63:613-20. 2011
    ..Additional improvements in terms of site specificity and protracted carrier retention at the site of injury may be expected from the development and use of magnetic carriers exhibiting affinity for arterial wall-specific antigens...
  4. ncbi Site-specific delivery of dexamethasone from biodegradable implants reduces formation of pericardial adhesions in rabbits
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
    J Biomed Mater Res A 78:276-82. 2006
    ....
  5. ncbi A new double emulsion solvent diffusion technique for encapsulating hydrophilic molecules in PLGA nanoparticles
    Einat Cohen-Sela
    Department of Pharmaceutics, Faculty of Medicine, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel
    J Control Release 133:90-5. 2009
    ..It is concluded that the new technique is advantageous in terms of smaller size, lower size distribution, higher encapsulation yield, and more biocompatible ingredients, with unaltered bioactivity...
  6. ncbi Magnetically responsive biodegradable nanoparticles enhance adenoviral gene transfer in cultured smooth muscle and endothelial cells
    Michael Chorny
    The Division of Cardiology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Mol Pharm 6:1380-7. 2009
    ..The enhancement of adenoviral gene delivery by affinity complexation with biodegradable MNP represents a promising approach with a potential to extend the applicability of the viral gene therapeutic strategies...
  7. ncbi High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents
    Boris Polyak
    Department of Surgery, Drexel University College of Medicine, Philadelphia, PA 19102, USA
    Proc Natl Acad Sci U S A 105:698-703. 2008
    ....
  8. ncbi Single and double emulsion manufacturing techniques of an amphiphilic drug in PLGA nanoparticles: formulations of mithramycin and bioactivity
    Einat Cohen-Sela
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P O Box 12065, Jerusalem 91120, Israel
    J Pharm Sci 98:1452-62. 2009
    ..The ineffectiveness in the rat restenosis model is probably due to the short depletion period of circulating monocytes and lack of arterial targeting...
  9. ncbi Magnetically targeted delivery of therapeutic agents to injured blood vessels for prevention of in-stent restenosis
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA, USA
    Methodist Debakey Cardiovasc J 8:23-7. 2012
    ..Studies showing the feasibility of this novel targeting strategy in in-stent restenosis models and considerations in the design of carrier formulations for magnetically guided antirestenotic therapy are discussed in this review...
  10. ncbi Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 107:8346-51. 2010
    ..5 microg PTX/stent). Thus, this study demonstrates the feasibility of site-specific drug delivery to implanted magnetizable stents by uniform field-controlled targeting of MNPs with efficacy for in-stent restenosis...
  11. ncbi Magnetically driven plasmid DNA delivery with biodegradable polymeric nanoparticles
    Michael Chorny
    Division of Cardiology Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104 4318, USA
    FASEB J 21:2510-9. 2007
    ..It is concluded that magnetically driven plasmid DNA delivery can be achieved using biodegradable MNP containing oleate-coated magnetite and surface modified with PEI oleate ion-pair complexes that enable DNA binding...
  12. ncbi Antioxidant enzymes reduce DNA damage and early activation of valvular interstitial cells in aortic valve sclerosis
    Emanuela Branchetti
    Research Assistant Professor of Surgery, Perelman School of Medicine, University of Pennsylvania, 500 S Ridgeway Ave, Room 257, Glenolden, PA 19036
    Arterioscler Thromb Vasc Biol 33:e66-74. 2013
    ..Because ROS cause DNA damage and transcriptional activation we investigated the relationship between ROS, DNA damage response, and transdifferentiation of VICs...
  13. ncbi Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries
    Shmuel Banai
    Heiden Department of Cardiology, Bikur Cholim Hospital, Jerusalem, Israel
    Biomaterials 26:451-61. 2005
    ..The results of this study suggest that locally delivered tyrphostin AGL-2043 formulated in biodegradable NP may be applicable for antirestenotic therapy independent of stent design or type of injury...
  14. ncbi Adenoviral gene vector tethering to nanoparticle surfaces results in receptor-independent cell entry and increased transgene expression
    Michael Chorny
    Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104-4318, USA
    Mol Ther 14:382-91. 2006
    ..It is concluded that Ad-specific affinity tethering to biodegradable NP can significantly increase the level of gene expression via a CAR-independent uptake mechanism...
  15. ncbi Study of the drug release mechanism from tyrphostin AG-1295-loaded nanospheres by in situ and external sink methods
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Israel
    J Control Release 83:401-14. 2002
    ....
  16. ncbi Site-specific gene therapy for cardiovascular disease
    Ilia Fishbein
    The Children s Hospital of Philadelphia, Abramson Research Center, Philadelphia, PA 19104, USA
    Curr Opin Drug Discov Devel 13:203-13. 2010
    ..This review summarizes progress made toward the site-specific delivery of cardiovascular gene therapy and highlights selected promising novel approaches...
  17. ncbi Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics
    Michael Chorny
    Department of Pharmaceutics, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, POB 12065, Israel
    J Control Release 83:389-400. 2002
    ..Nanoprecipitation protocol modifications were suggested to produce nanospheres combining ultrasmall size (<100 nm) with high drug recovery yield, and to reduce the surfactant amount in the formulation...
  18. ncbi Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries
    Shmuel Banai
    Department of Cardiology, Hadassah University Hospital, P.O. Box 12000, Jerusalem 91120, Israel
    Cardiovasc Res 64:165-71. 2004
    ..Long-term studies should be the next step in testing applicability to the human interventional setting...